Evidence map›Paper›PMID 39299233›Full record

ArticleCell2024

High-resolution functional mapping of RAD51C by saturation genome editing.

Rebeca Olvera-León, Fang Zhang, Victoria Offord, Yajie Zhao, Hong Kee Tan, Prashant Gupta, Tuya Pal, Carla Daniela Robles-Espinoza, Fernanda G Arriaga-González, Larissa Satiko Alcantara Sekimoto Matsuyama and 10 more

Abstract read
In one paragraph

Article in Cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Review
  3. AlphaGenome Atlas:medRxiv : the preprint server for health sciences · 2026
    Article
  4. Article
  5. Reclassification ofCurrent oncology (Toronto, Ont.) · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Functional dissection ofProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Saturation Genome Editing TargetingCurrent issues in molecular biology · 2026
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Rebeca Olvera-LeónWellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK; Laboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, Querétaro, Mexico.
Fang ZhangMeinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA; Developmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Victoria OffordWellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.
Yajie ZhaoMRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, UK.
Hong Kee TanWellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.
Prashant GuptaWellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.
Tuya PalDepartment of Medicine, Division of Genetic Medicine, Vanderbilt University Medical Center (VUMC)/Vanderbilt-Ingram Cancer Center (VICC), Nashville, TN, USA.
Carla Daniela Robles-EspinozaWellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK; Laboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, Querétaro, Mexico.
Fernanda G Arriaga-GonzálezWellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK; Laboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, Querétaro, Mexico.
Larissa Satiko Alcantara Sekimoto MatsuyamaWellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.
Erwan DelageWellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.
Ed DicksDepartment of Public Health and Primary Care, University of Cambridge, Robinson Way, Cambridge, UK.
Suzana EzquinaDepartment of Public Health and Primary Care, University of Cambridge, Robinson Way, Cambridge, UK.
Charlie F RowlandsDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Clare TurnbullDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK; National Cancer Registration and Analysis Service, National Health Service (NHS) England, London, UK; Cancer Genetics Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Paul PharoahDepartment of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
John R B PerryMRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, UK.
Maria JasinDevelopmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andrew J WatersWellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK. Electronic address: aw28@sanger.ac.uk.
David J AdamsWellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK. Electronic address: da1@sanger.ac.uk.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Homology-directed repair: BRCA2 and RAD51 paralogsR35CA253174 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Maria Jasin · 2020 to 2026
$6.7M
NCI NIH HHS P30 CA008748NCI NIH HHS R35 CA253174Wellcome Trust
6 · The paper itself

Abstract

Pathogenic variants in RAD51C confer an elevated risk of breast and ovarian cancer, while individuals homozygous for specific RAD51C alleles may develop Fanconi anemia. Using saturation genome editing (SGE), we functionally assess 9,188 unique variants, including >99.5% of all possible coding sequence single-nucleotide alterations. By computing changes in variant abundance and Gaussian mixture modeling (GMM), we functionally classify 3,094 variants to be disruptive and use clinical truth sets to reveal an accuracy/concordance of variant classification >99.9%. Cell fitness was the primary assay readout allowing us to observe a phenomenon where specific missense variants exhibit distinct depletion kinetics potentially suggesting that they represent hypomorphic alleles. We further explored our exhaustive functional map, revealing critical residues on the RAD51C structure and resolving variants found in cancer-segregating kindred. Furthermore, through interrogation of UK Biobank and a large multi-center ovarian cancer cohort, we find significant associations between SGE-depleted variants and cancer diagnoses.

Indexed as

DNA-Binding ProteinsGene EditingOvarian NeoplasmsAllelesBreast NeoplasmsCRISPR-Cas SystemsFemaleHumansDNA-Binding ProteinsRAD51C protein, humancancer predispositionhomologous recombinationRAD51Csaturation genome editing

Identifiers

PMID39299233
PMCPMC12147941

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.